China's FDA signs MoU on strategic cooperation with the Gates Foundation

13 June 2016

China Food and Drug Administration’s (CFDA) Minister Bi Jingquan and Bill & Melinda Gates Foundation co-chairman Bill Gates recently officially signed the Memorandum of Understanding on Strategic Cooperation between the CFDA of the People's Republic of China and the Gates Foundation.

According to the MoU, both sides will cooperate to improve China’s drug supervision capability and drug technical standards, and establish the mechanism of introducing international high-end talent of drug supervision and fostering internationalized supervision talents.

Under the MoU, efforts will be made to implement the international expert introduction projects for drug evaluation and inspection, and set up drug supervision think tank to support China's reform of drug evaluation and approval system.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK